300,000+ clinical trials. Find the right one.

46 active trials for Hypoxia

Servo Controlled Oxygen Targeting (SCO2T) Study: Masimo vs. Nellcor

Most premature babies require oxygen therapy. There is uncertainty about what oxygen levels are the best. The oxygen levels in the blood are measured using a monitor called a saturation monitor and the oxygen the baby breathes is adjusted to keep the level in a target range. Although there is evidence that lower oxygen levels maybe harmful, it is not known how high they need to be for maximum benefit. Very high levels are also harmful. Saturation monitors are not very good for checking for high oxygen levels. For this a different kind of monitor, called a transcutaneous monitor, is better. Keeping oxygen levels stable is usually done by nurses adjusting the oxygen levels by hand (manual control). There is also equipment available that can do this automatically (servo control). It is not known which is best. Research suggests that different automated devices control oxygen effectively as measured by the readings from their internal oxygen saturation monitoring systems. When compared to free-standing saturation monitors there appears to be variations in measured oxygen levels between devices. This could have important clinical implications. This study aims to show the different achieved oxygen levels when babies are targeted to a set target range. Babies in the study will have both a saturation monitor and a transcutaneous oxygen monitor at the same time. Both types of monitor have been in long term use in neonatal units. For a period of 12 hours, each baby will have their oxygen adjusted automatically using two different internal oxygen monitoring technologies (6 hours respectively). The investigators will compare the range of oxygen levels that are seen between the two oxygen saturation monitoring technologies. The investigators will study babies born at less than 30 weeks gestation, who are at least 2 days old, on nasal high flow and still require added oxygen.

Start: November 2020
RCT of Efficacy of Amoxicillin Over Ampicillin on Severe Pneumonia

Burden: Pneumonia remains the leading infectious cause of death accounting 920,000 children under five around the world. This means a loss over 2,500 child lives every day, or over 100 every hour. Since 2000, the number of child deaths caused by pneumonia has decreased by 47 per cent. The tremendous progress made is due in part to the rapid roll-out of vaccines, better nutrition and improved care-seeking and treatment for symptoms. However, pneumonia hasn't declined as quickly as other diseases such as malaria (58%), HIV/AIDS (61%) and measles (85%). Knowledge gap: The Lancet Series on Childhood Pneumonia and Diarrhea has reported that case management is one of the three most effective interventions to reduce pneumonia deaths in children. It is also noted that cost effectiveness of these interventions in national health system needs urgent assessment. It was suggested to find out means to reduce hospital stay without compromising the quality of care. Relevance: The main purpose of our study is to compare the efficacy of two doses of parenteral Amoxicillin plus single dose Gentamicin compared to four doses of parenteral Ampicillin plus single dose Gentamicin. After 72 hours of treatment injectable Amoxicillin or injection Ampicillin will be switched to or replaced by oral Amoxicillin and will be discharged with an advice to attend to Ambulatory Care Unit (ACU) to receive once daily dose of injection Gentamicin for total 5 days. It is anticipated that this modified therapy will reduce hospitalization stay of children with severe pneumonia and would therefore be relevance in countries with resource poor setting. By reducing hospitalization period, this therapy has potentials to reduce hospital acquired infection. Hypothesis (if any): Rate of treatment failure with two doses of injectable Amoxicillin plus single dose Gentamicin will be not more than that of four doses of injectable Ampicillin plus single dose Gentamicin in the management of children between 2 months to 59 months hospitalized for WHO classified severe pneumonia.

Start: January 2018